News
Investing.com -- IO Biotech (NASDAQ: IOBT) stock rose 6.1% after announcing topline results from its pivotal Phase 3 trial of Cylembio, an investigational cancer vaccine, in combination with Merck ...
BioNTech stock was rising after the drugmaker reported better-than-expected results on Monday. In early trading, the ...
5don MSNOpinion
U.S. to phase out funding for mRNA vaccine development
Global vaccine stocks in focus as the U.S. government plans to phase out investment for mRNA vaccine development activities.
4d
Novavax stock surges as HHS pulls mRNA vaccine funding, opening doors for alternative technologies
The federal government’s move to pull hundreds of millions of dollars in funding for mRNA vaccines could be a shot in the arm ...
(Reuters) -Shares of global vaccine makers were mixed on Tuesday, as investors assessed U.S. Health Secretary Robert F. Kennedy Jr.'s surprising decision to fire all 17 members of a key expert ...
Jerome Adams, the U.S. Surgeon General under President Trump's first term, is criticizing his administration's cuts to mRNA ...
The signs of a potential bird flu transmission have provided some respite to these vaccine-focused stocks, especially for those involved in the COVID-19 vaccine roll-out.
4don MSN
What to know about mRNA vaccines
WASHINGTON -- So-called mRNA vaccines saved millions of lives during the COVID-19 pandemic — and now scientists are using ...
Danger Is Approaching for Coronavirus Vaccine Stocks As the race for a Covid-19 vaccine enters the final stretch, investors should be more wary of common drug development pitfalls By Charley Grant ...
Trump administration has unwisely cancelled mRNA vaccine research while doing little about Americans’ unhealthy diet.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback